Back to Results

A PHASE 1 STUDY OF FOR46 ADMINISTERED EVERY 21 DAYS IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM)

Primary Objective

Evaluate the safety and tolerability of FOR46 at escalating dose levels and administered intravenously (IV) every 21 days in relapsed/refractory multiple myeloma patients. And determine the maximum-tolerated dose and/or the recommended Phase 2 dose (RP2D) of FOR46 administered IV every 21 days in relapsed/refractory multiple myeloma patients.

Study category: Cancer

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Type of Study

Treatment

Location

University of Colorado Hospital

Principal Investigator
Tomer Mark,  MD

Tomer Mark, MD

Study ID

Protocol Number: 18-2354

More information available at ClinicalTrials.gov: NCT03650491

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers